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INTRODUCTION 
 
Chemotherapy-induced  ovarian  failure  not  only 
increases  the  risk  for  early  menopause-related 
complications  but  also  results  in  infertility  in  young 
female  cancer  survivors  [1,2].  In  general,  underlying 
mechanisms  of  this  chemotherapy-induced  ovarian 
aging is inadequately characterized in humans. 
 
The goal of this study was to explore the mechanism of 
the acceleration of human ovarian aging as a result of 
chemotherapy.  To investigate this effect we utilized a 
commonly  administered  cancer  chemotherapeutic, 
doxorubicin, in an in vivo xenograft as well as in vitro 
models, using a double-species approach. DNA damage 
response  induced  by  doxorubicin  was  assessed 
immunocytochemically  by  detecting  histone  H2AX 
phosphorylation on Ser139 [3] and activation of Ataxia 
Telangiectasia Mutated protein kinase (ATM) through 
its  phosphorylation  on  Ser1981,  using  the  respective 
phospho-specific  Abs  [4].    The  extensive  nuclear 
labeling  with  these  Abs,  especially  in  form  of 
characteristic foci, is considered to report the presence 
of DSBs, the potentially lethal DNA lesions. 
 
METHODS 
 
This study was carried out in strict accordance with the 
recommendations in the Guide for the Care and Use of 
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Abstract: The mechanism of chemotherapy-induced acceleration of ovarian aging is not fully understood. We used 
doxorubicin, a widely used cancer chemotherapeutic, in a variety of in vivo xenograft, and in vitro models to investigate 
the impact of chemotherapy-induced aging on the human ovary.  Doxorubicin caused massive double-strand-DNA-
breaks in primordial follicles, oocytes, and granulosa cells in a dose dependent fashion as revealed by accumulating 
γH2AX foci. This damage was associated with apoptotic oocyte death and resulted in the activation of ATM. It appeared 
that the repair response enabled a minor proportion of oocytes (34.7%) and granulosa cells (12.1%) to survive while the 
majority succumbed to apoptotic death. Paradoxically, inhibition of ATM by KU-55933 resulted in improved survival, 
probably via prevention of downstream activation of TAp63α. Furthermore, doxorubicin caused vascular and stromal 
damage in the human ovary, which might impair ovarian function both pre- and post-menopausally. Chemotherapy-
induced premature ovarian aging appears to result from a complex process involving both the germ- and non-germ cell 
components  of  the  ovary.  These  effects  may  have  clinical  implications  in  aging  both  for  premenopausal  and 
postmenopausal cancer survivors. 
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Laboratory Animals of the National Institutes of Health 
and  the  New  York  Medical  College  (NYMC) 
Institutional  Animal  Care  and  Use  Committee.  The 
study protocol was approved by the institutional review 
board  of  NYMC  and  written  informed  consent  was 
obtained from all participants involved in the study. All 
surgery was performed under anesthesia, and all efforts 
were  made  to  minimize  suffering.  Ovarian  tissue 
fragments  were  obtained  from  consenting  females 
patients, or their parents in the case of minors, (n=6, age 
range  2-37)  during  ovarian  tissue  cryopreservation 
procedures before chemotherapy. 
 
The effect of doxorubicin was studied both with in vitro 
cultured human ovarian cortical tissue (OCT) and an in 
vivo  human  to  severe  combined  immunodeficiency 
(NOG-SCID) (Taconic, USA) mice xenotransplantation 
model, as well as in in vivo mouse experiments. 
 
Human ovarian tissue culture 
 
OCTs  were  cut  into  1mm
3  pieces.  They  were  then 
randomly selected and cultured in multi-well plates (# 
35-3078,  Becton,  Dickinson,  NJ,  USA)  with  MEM-
alpha  medium  (Gibco,  Invitrogen,  Carlsbad,  USA) 
supplemented  with  10%  bovine  serum  albumin 
(v/v)(Sigma-Aldrich,  St.  Louis,  MO,  USA)  and  1% 
insulin-transferrin-selenium  (Gibco,  Invitrogen, 
Carlsbad,  USA)  containing  1,  10  and  100  µg/ml  of 
doxorubicin (Sigma-Aldrich, St Louis, MO, USA) for 
24-72h (n=8 in each experimental point).  In controls, 
vehicle (sterile normal saline) was added to the culture 
medium in control group. Cultured OCT samples were 
recovered  and  processed  for  further  histological 
evaluation. 
 
Human ovarian tissue xenografting 
 
OCT  pieces  (1mm
3)  were  selected  randomly  and 
transplanted into the dorsal muscles of seven-week-old 
SCID  mice  (NOG,  Taconic,  USA)  as  previously 
described  (13-16)  (n=8).  Briefly,  human  ovarian 
fragments  were  collected  in  modified  M199  medium 
(Gibco, Invitrogen, Carlsbad, USA). Recipient animals 
were  anesthetized  by  ketamine  75  mg/kg  i.p. 
(Ketathesia,  OH,  USA)  and  xylazine  1  mg/kg  i.p. 
(AnaSed,  Shanandoah,  Iowa,  USA)  [5].  A  small 
incision was made in the skin on the dorsal midline of 
the recipient animal, and OCT pieces (n=2/animal) were 
transplanted into the dorsal muscles in recipient mice by 
means  of  a  fine  watchmakers’  forceps.  Skin  incision 
was  closed  under  aseptic  conditions.  Animals  were 
allowed  to  recover  for  ten  days  and  10  mg/kg 
doxorubicin  was  administered  to  the  xenografted 
animals intravenously. In contrast, control animals were 
treated  with  vehicle.  OCT  grafts  were  recovered  24h 
later  and  analyzed  for  vascular  density  by  CD31 
expressing  micro-vessels/mm
2  field,  percentage  of 
primordial follicles with DSBs by γH2AX staining and 
those that are apoptotic by AC3 expression. 
 
In vivo assessment of the impact of doxorubicin in 
the mouse ovary   
 
Due to the non-uniformity of human primordial follicles 
distribution in OCTs, the number of primordial follicles 
and  apoptotic  follicles  densities  were  compared  in 
ovaries of doxorubicin-treated SCID mice compared to 
vehicle-treated controls (n=6). 
 
Furthermore, to study the in vivo effect of doxorubicin 
on ovarian follicles and their cumulus cells, mice (n=7) 
(B6D2 and FBV, Taconic, USA) were injected with a 
single  dose  of  doxorubicin  10  mg/kg.  Animals  were 
sacrificed  24h  later,  ovaries  were  collected,  small 
preantral  follicles  (100–120  µm  in  diameter)  (n=140) 
and GV oocytes (n=94) were mechanically isolated by a 
fine needle (25 5/8-G; Becton–Dickinson NJ, USA) and 
fixed in 4% of methanol-free formaldehyde dissolved in 
phosphate buffered saline (PBS) washed and stored in 
blocking solution. Blocking solution was composed of 
2% (v/v) normal goat serum (Gibco, Bornem, Belgium), 
0.2%  (w/v)  powdered  milk  (Bio-Rad,  Hercules,  CA, 
USA), 1% (w/v) bovine serum albumin (BSA, Sigma-
Aldrich, St. Louis, MO, USA), 0.1M glycine (Bio-Rad), 
0.01% Triton X-100  (Bio-Rad),  in PBS  (Calbiochem, 
Darmstad, Germany) with 0.2% sodium azide (Sigma-
Aldrich,).  Oocytes  and  follicles  were  evaluated  with 
laser scanning confocal microscopy (LSM170, ZEISS, 
Imager Z1) using a Zen 2008 imaging program, after 
being  stained  for  anti-active-Caspase-3  (AC3,  R&D 
systems,  Minneapolis,  USA),  phospho-ataxia-
telangiectasia-mutated  (ATM,  Millipore,  Temecula, 
CA,  USA)  and  γH2AX  (BioLegend,  San  Diego,  CA, 
USA).  The  percentage  of  granulosa  cells  from  small 
preantral  follicles  positive  for  DSBs  by  γH2AX, 
apoptotic  by  AC3,  and  the  ATM  expression  were 
compared  to  vehicle-treated  controls.  Vehicle-treated 
animals  served  as  control.  The  extent  of  DSBs  was 
further  investigated  by  single  cell  gel  electrophoresis 
(Comet assay) [6]. Briefly, GV oocytes were obtained 
and the granulosa cells were removed enzymatically by 
short incubation in hyaluronidase and the zona pellucida 
was removed by incubation in acid Tyrode`s solution.
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Following the lysis of the oocytes with detergent at high 
salt  concentration,  electrophoresis  was  performed  at 
neutral  PH  to  facilitate  the  detection  of  DSBs  (7.4). 
Chromatin  staining  was  performed  with  propidium 
iodide.  The  extent  of  DNA  migration  was  quantified 
using  comet  score  program  (TriTech  Corporation, 
Sumerduck, VA, USA) and expressed as the percentage 
of DNA in the tail and compared with non-doxorubicin-
treated  oocytes.  All  the  products  used  for  this 
experiment were bought from Sigma-Aldrich, St. Louis, 
MO, USA, unless otherwise mentioned. 
 
Ovarian tissue histology and immunohistochemistry 
 
OCT  samples  were  recovered  and  processed  for 
hematoxylin-eosin  staining  (H&E)  and 
immunohistochemistry (IHC) with activated caspase-3 
(AC3) antibodies for the detection of apoptosis.  The 
number  of  apoptotic  follicles  was  expressed  as  the 
fraction  of  total  follicle  numbers  in  each  square 
millimeter of tissue. Tissues were also evaluated for the 
presence  of  new  (CD31,  Abcam,  MA,  USA)  and 
existing  mature  blood  vessels  (alpha  smooth  muscle 
actin) (α-SMA, Ventana, Lille, France) by IHC staining. 
Blood vessels were counted and averaged at high power 
field magnification (×400) in a grid area of 0.15 mm
2 at 
five randomly selected positions in twenty-five different 
sections of each tissue sample [5,7]. The presence of 
characteristic  nuclear  foci  after  immunostaining  for 
γH2AX  (Bethyl  Laboratory,  Montgomery,  TX,  USA) 
was considered to represent the induction of DSBs and 
the percent of oocytes expressing distinct γH2AX foci 
was visually assessed under microscope.   
 
Figure 1. Induction of double strand DNA breaks in human primordial follicles by doxorubicin. γH2AX-
positive (black arrows) and negative (white arrows) primordial follicles in human ovarian cortical pieces after in 
vitro culture with doxorubicin doses of 1-100 mg/ml for 24 or 72h. A-C) Doxorubicin induces DSBs in a dose-
dependent fashion after 24h of culture. Note the massive induction of DSBs in primordial follicles after 24h 
culture with doxorubicin 100 mg/ml. D) Vehicle control at 72h. E-G) Doxorubicin treatment at 100 mg/ml for 72h 
also causes ovarian tissue necrosis along with massive γH2AX expression in stromal cells. H) Negative control, 
secondary antibody omitted. I) Induction of DSBs was positively correlated with the dose of doxorubicin after 24-
72h  culture  (Spearman`s  rank  correlation  coefficient:  0.967;  p<0.001).  J)  High  number  of  γH2AX-positive 
primordial  follicles  in  a  xenograft  from  a  SCID  mouse  treated  with  10mg/kg  doxorubicin.  K)  Vehicle-treated 
(control) human ovarian tissue xenograft. 
# Significantly different from the control 24h 
*Significantly different from the control 
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Statistical analysis 
 
SPSS  17  for  Windows  package  (SPSS  Inc.,  Chicago, 
IL)  was  used  for  statistical  analysis.  To  choose  the 
appropriate statistical test, Levene’s test of homogeneity 
of variances (p<0.01) and Kolmogorov-Smirnov test of 
normality  (p<0.01)  were  performed.  Continuous  data 
(presented  as  mean±SD)  were  analyzed  by  one-way 
analysis of variance followed by the LSD post hoc test. 
The  non-parametric  data  were  analyzed  with  the 
Kruskal-Wallis  test  followed  by  multiple  pair-wise 
comparisons using Mann-Whitney U-test (α value was 
adjusted).  To  analyze  the  relation  between  two 
categorical variables, Fisher’s exact test was performed. 
Non-parametric correlation  between the percentage of 
apoptotic follicles and the number of blood vessels was 
analyzed with the Spearman’s test. The difference was 
considered  statistically  significant  if  the  P  value  was 
<0.05. 
 
RESULTS 
 
Doxorubicin induces double strand DNA breaks in 
human ovary as reported by γH2AX expression 
 
For in vitro experiments, human ovarian cortical pieces 
were cultured for 24-72h with or without doxorubicin at 
1, 10, 100 µg/ml doses and primordial follicle densities 
were compared. The presence of γH2AX, the reporter of 
DSBs [3,4] and primordial follicle apoptosis, detected 
by  the  activated  caspase-3,  were  studied  in  adjacent 
OCT  sections.  A  significantly  higher  percentage  of 
γH2AX-positive primordial follicles were observed in 
OCTs incubated with 1 µg/ml doxorubicin for 24h in 
comparison  to  vehicle-treated  controls  (45.2±7.3  vs. 
26.5±2.9 %, p=0.005) and 72h (53.2±1.7 vs. 31.7±4.5 
%, p<0.001) (Figure 1, A-H). Treatment with 10 µg/ml 
doxorubicin resulted in a significantly higher percentage 
of γH2AX-positive primordial follicles both after 24h 
(77.5±7.4 %, p<0.001) and 72h (96.2±7.2 %, p<0.001) 
compared to control. Doxorubicin 100 µg/ml induced 
massive γH2AX labeling in ovarian follicles regardless 
of the incubation time (94.8± 2.4 and 99.1±1.7 %, 24h 
and  72h  respectively,  p<0.001).  A  significant 
correlation  was  observed  between  the  dose  of 
doxorubicin and the percentage of γH2AX-foci positive 
primordial follicles in cultured OCTs (Spearman`s rank 
correlation coefficient: 0.967; p<0.001) (Figure 1, I). 
 
To translate the in vitro findings to the in vivo setting, 
SCID mice were xenografted with human ovarian tissue 
and received 10 mg/kg of doxorubicin as described in 
the methods section. Doxorubicin treatment resulted in 
a  significantly  higher  percentage  of  γH2AX-positive 
Figure 2. Induction of apoptotic primordial follicle death by doxorubicin. AC3-positive (black arrows) 
and negative (white arrows) primordial follicles and apoptotic vasculature (red arrow) in human ovarian cortical 
pieces. A-D) Doxorubicin induces apoptosis of human primordial follicles after 24h culture in 10 and 100 μg/ml 
concentrations. E) Vehicle control at 72h. F) Negative control are shown where primary antibody omitted. G) A 
significant correlation was observed between the dose of doxorubicin and percentage of apoptotic primordial 
follicles  in  cultured  OCTs  (Spearman`s  rank  correlation  coefficient:  0.785;  p=0.0001).  H)  A  high  number  of 
apoptotic primordial follicles was seen in human ovarian tissue xenografted into the dorsal muscle of SCID mouse 
after treatment with 10mg/kg doxorubicin. I) Xenogafted vehicle-treated control. 
*Significantly different from controls at 24 or 72h. 
#Significantly different from 1 µg/ml doxorubicin dose at 24 and 72h. 
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primordial  follicles  compared  to  vehicle  treatment 
(58.1±1.0 vs. 15.6±0.9 %, p<0.001) (Figure1, J and K). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Doxorubicin  induces  apoptotic  death  of  human 
ovarian follicles 
 
Doxorubicin  caused  apoptosis  in  a  dose-dependent 
manner  when  evaluated  by  AC3  staining  in  vitro 
(Figure 2, A-F). The percentage of follicles undergoing 
apoptosis  increased  at  both  10  and  100  µg/ml  but 
statistical  significance  was  noted  only  with  the  100 
µg/ml dose of doxorubicin after 24 and 72h of culture 
(57 and 59 % of follicles in doxorubicin-treated vs. 14 
and  25  %  in  vehicle-control  at  24h  and  72h, 
respectively,  p<0.001).  A  significant  correlation  was 
observed  between  the  dose  of  doxorubicin  and  the 
percentage of apoptotic primordial follicles in cultured 
OCTs (Spearman`s rank correlation coefficient: 0.785; 
p=0.0001)(Figure 2, G).  
 
Consistent with in vitro findings, in vivo doxorubicin 
treatment  induced  a  significantly  higher  level  of 
apoptosis in xenografted primordial follicles (55.4±5.7 
vs.  11.8±5.7  %,  p<0.005)  treated  with  doxorubicin 
compared to vehicle-treated controls (Figure 2, H and 
I). In addition, the ovaries of SCID mice that were used 
in  the  human  xenografting  experiments  showed  that 
doxorubicin  treatment  significantly  reduced  the  mean 
density  of  primordial  follicles  (4.31±2.1  vs. 
10.57±6.7/mm
2,  p<0.001)  compared  to  vehicle-treated 
controls  similar  to  its  effect  in  human  ovarian 
xenografts in the same mice, doxorubicin treatment also 
induced a significantly higher percentage of apoptotic 
follicles  in  primordial  (47.1±12.8  vs.  0.4±1.4  %, 
p<0.001), primary (44.7±12.2 vs. 4.1±5.9 %, p<0.001) 
and  developing  (49.5±8.6  vs.  6.9±5.5  %,  p<0.001) 
follicles  as  well  as  inducing    γH2AX  expression  
(Figure 3). In these follicles, co-expression of AC-3 and 
γH2AX suggested that unrepaired DSBs were resulting 
in apoptotic death. 
 
Doxorubicin  causes  microvascular  and  stromal 
damage in human ovary 
 
The density of newly forming ovarian microvessels was 
determined  by  CD31-expression  in  micro  vessels  per 
mm
2  after  treatment  with  doxorubicin.  The  results 
showed  a  decrease  in  vascular  density  with  the  72h 
culture  after  1  µg/ml  (26.5±8.4/mm
2,  p<0.001),  10 
µg/ml  (25.5±7.8/mm
2,  p<0.05),  and  100  µg/ml 
doxorubicin  (20.8±5.1/mm
2,  p<0.05)  compared  to 
vehicle treatment (39.4 ±5.7/mm
2)(Figure 4, A-D). In 
contrast,  blood  vessel  density  increased  significantly 
after 72h culture in vehicle-treated controls compared to 
the  uncultured  baseline  tissue  (39.4±5.7/mm
2  vs. 
30.0±6.2/mm
2, p<0.001), (Figure 4, D and E), due to 
expected  continuation  of  microvessel  proliferation. 
There was also a significant decrease in the density of 
mature blood vessels as determined by αSMA IHC after 
72h  culture  with  10  µg/ml  (4.0±2.0  vs.  9.5±3.5, 
p=0.002)  and  100  µg/ml  doxorubicin  (4.7±3.1  vs. 
9.5±3.5,  p=0.04)  compared  to  controls.  A  significant 
inverse-correlation was observed between the dose of 
doxorubicin and the density of αSMA-positive vessels 
(Spearman`s  rank  correlation  coefficient:  -0.798; 
p<0.001)(Figure  4,  F).  Furthermore,  after  72h  culture 
with doxorubicin 1, 10 and 100 µg/ml, multiple necrotic 
areas  were  seen  in  OCTs  (7.3±5.1,  mean  number  of 
necrotic  areas/graft)(Figure  4,  G).  Validating  and 
confirming  in  vitro  organ  culture  experiments, 
doxorubicin treatment also resulted in reduced vascular 
density in xenografted human ovarian tissues compared 
to  vehicle-treated  controls  (6.4±1.9  vs.  13.9±2.1, 
p<0.001)(Figure 4, H and I). 
 
Figure 3. Induction of DSBs and apoptotic follicle death 
by  doxorubicin  in  xenografted  SCID  mouse  ovaries. 
Ovaries of xenografted SCID mice were recovered 24h after a 
single injection of doxorubicin 10 mg/kg and stained for  γH2AX 
and  AC3.  A)  γH2AX-positive  primordial  follicle  oocytes 
(highlighted)  in  lower  magnification.  Note  γH2AX  staining  in 
granulosa  cells  but  not  the  oocyte  of  the  adjacent  preantral 
follicle. B) Higher magnification of the primordial follicle in solid 
square with yH2AX staining. C) The same primordial follicle in B 
shows AC3-positive staining on the adjacent section, suggesting 
that DSBs induced apoptotic follicle death. D) Negative control. 
Primary antibody omitted, same follicle as in B & C, on adjacent 
section,  E)  Higher  magnification  of  γH2AX-positive  primordial 
follicle from panel A, in dashed square. F) AC3-positive staining 
of the same follicle in D on adjacent section. 
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Doxorubicin induces γH2AX in immature (GV) mice 
oocytes and small ovarian preantral  follicles, while 
activating ATM-pathway response 
 
To  further  delineate  and  confirm  the  impact  of 
doxorubicin on double strand DNA and the involvement 
of  ATM-mediated  DSB  repair  response,  GV  oocytes 
and  small  preantral  follicles  were  collected  from  the 
ovaries  of  doxorubicin-  or  vehicle-treated  mice  and 
evaluated  by  confocal  microscopy.  A  significantly 
higher  number  of  GV  oocytes  in  doxorubicin-treated 
animals  demonstrated  multi-nucleation  compared  to 
vehicle-treated  controls  (28.2±6.0  vs.  4.9±4.0,  p 
<0.001) (Figure 5, A and B) consistent with chromatin 
damage and genotoxicity [8,9]. In parallel with multi-
nucleation, the mean number of γH2AX foci (64.1±29.8 
vs. 11.5±7.3, p<0.05) and the percentage of apoptotic 
follicles  (42.7±11.6  vs.  2.7±3.8,  p<0.05)  were 
significantly higher in GV oocytes from doxorubicin-
treated  ovaries  compared  to  vehicle-treated  controls 
(Figure 5, C and D). 
 
The comet assay is based on the ability of negatively 
charged fragments of DNA to move through an agarose 
gel in response to an electric field. The extent of DNA 
migration depends directly on the DNA damage present 
in  the  cells.  The  alkaline  version  of  the  comet  assay 
enables the detection of DNA single-strand breaks and 
alkali-labile  lesions  (DNA  breaks  that  only  become 
apparent after exposure to alkali) while electrophoresis 
at neutral conditions detects DSBs[6]. To confirm that 
increased γH2AX foci reflected DSBs, we performed a 
neutral pH comet assay on GV oocytes treated in vitro 
with doxorubicin 10 µg/ml. for 24h and found similar 
results (Fig 6). 
 
Having shown that doxorubicin causes DSBs resulting 
in apoptotic death in oocytes, we next studied the DNA 
repair response. To study the DNA repair response, we 
analyzed  expression  of  activated  ATM.  Compared  to 
vehicle-treated  controls,  doxorubicin  treatment 
increased ATM activation both in the nucleus (7.1±1.4 
vs.  224.5±42.2,  p<0.001)  and  the  cytoplasm 
(142.2±30.1 vs. 186.3±27.6, p<0.05) (Figure 5, E and 
F). Moreover, the same treatment caused a change in 
the localization of ATM. While in control oocytes the 
predominant  fraction  of  ATM  was  in  the  cytoplasm 
(142.2±30.  vs.  7.1±1.4  in  nucleus,  p<0.001)  after 
doxorubicin treatment (Figure 5, E), a larger proportion 
was located in the nucleus (224.5±42.2 vs. 186.3±27.6 
in cytoplasm, p<0.05)(Figure 5, F). The latter indicates 
a  significant  translocation  of  phospho-ATM  from 
cytoplasm to nucleus. 
 
Unrepaired  DSBs  will  result  in  the  activation  of 
apoptotic pathways via the ATM-pathway [10] or cell 
cycle arrest [11]. We therefore assessed the relationship 
between  γH2AX  staining  and  apoptotic  oocyte  death. 
Of  the  γH2AX-positive  oocytes,  66.3  ±12.8%  were 
apoptotic and the remainder were non-apoptotic based 
Figure 4. The impact of doxorubicin on vascular density in ovarian cortical pieces. A-C) CD31-positive 
blood vessels in human ovarian cortical pieces cultured with different doses of doxorubicin for 72h. Doxorubicin 
treatment results in decreased density of blood vessels in a dose dependent manner. Vehicle-treated control. E) 
CD31-positive blood vessels are shown at baseline in ovarian tissue. F) Doxorubicin caused a significant decrease 
in ovarian vascular density after 72h for all doses but not 24h culture compared to controls at all three doses 
tested.  G)  Doxorubicin-induced  necrosis  and  stromal  cell  death  in  vitro  (red  arrow).  H&I)  Similar  to  in  vitro 
experiments, doxorubicin reduced vascular density in xenografts compared to vehicle-treated control xengrafts. 
Black arrows show CD31-positive blood vessels in human ovarian cortical pieces. 
*Significantly different from the control (72h). 
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on  AC-3  staining.  This  suggests  that  either  the  DNA 
damage was not sufficient to induce cell death, or DNA 
repair mechanisms were successful and prevented cell 
demise. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To demonstrate that ATM activation was involved in 
and is related to oocyte survival or apoptotic death after 
doxorubicin-induced  DNA  damage,  we  pretreated  
mouse GV oocytes with ATM inhibitor KU-55933, 10 
μMol (Tocris Bioscience, Missouri, USA) or its vehicle 
(dimethyl sulfoxide, Sigma) for 3h prior to doxorubicin 
treatment (1 μg/ml). Oocyte apoptosis was assessed 24h 
later.  In  the  ATM-inhibited  group,  percentage  of 
apoptotic oocytes was significantly reduced compared 
to the non-ATM-inhibited (28.6% vs. 64.1%; p<0.05). 
These data indicate that ATM activation is involved in 
chemotherapy-induced  oocyte  death  and  is  consistent 
with  the  previous  data  in  lymphoblastoid  cells  that 
inhibition of ATM rescues from tumor necrosis factor- 
related  apoptosis-inducing  ligand  induced  apoptotic 
death  [12].  Interestingly,  doxo  treatment  blocked  cell 
cycle progression beyond Metaphase I (MI) stage but 
ATM inhibitor treatment did not significantly affect this 
inhibition. One hundred percent in the doxo group and 
92.1%  in  the  doxorubicin+ATM  inhibitor  group 
arrested at GV or MI compared to 17.7% in the control 
group after 24h in culture (P<0.001). 
 
TAp63α  is  involved  in  female  germline  survival  and 
ATM  has  been  shown  to  regulate  c-Abl-TAp63 
pathway[13,14,15].  Thus  we  wanted  to  determine 
whether the reduction of doxo-induced apoptotic death 
of oocytes in response to the ATM inhibitor was due to 
prevention  of  ATM-induced  activation  of  the  c-Abl-
TAp63 pathway. By confocal imaging, we found that 
ATM inhibition with KU-55933 also inhibited TAp63 α 
and  c-Abl  activation  in  the  nuclei  of  doxo-treated 
oocytes  (supplementary  figure  1).  The  inhibition  of 
TAp63 was more profound, with KU-55933 completely 
blocking  phosphorylation  of  TAp63  in  response  to 
genotoxic  effects  of  doxorubicin.  This  suggests  that 
ATM  is  regulating  TAp63  α  activation  both  c-Abl 
dependent and independent pathways, the latter being 
the predominant form. 
 
Doxorubicin treatment also resulted in a significant rise 
in  the  percentage  of  apoptotic  cumulus  cells 
surrounding  the  oocytes  compared  to  controls 
(27.7±10.3 vs. 2.4±0.6, p<0.001) (Figure 5, C and D). 
Thus we also studied cell survival and DNA damage in 
granulosa  cells  of  small  follicles  isolated  from 
doxorubicin-treated mice. Consistent with its effect in 
GV  oocytes,  doxorubicin  compared  to  vehicle 
treatments  resulted  in  a  significant  increase  of  cells 
expressing  γH2AX  (53.8±12.3  vs.  2.1±0.4,  p<0.001) 
and  induction  of  apoptosis  in  granulosa  cells 
(35.9±14.6% vs. 3.7±2.0%, p<0.001)(Figure 5, G-J). In 
doxorubicin-treated  follicles    higher  percentage  of 
granulosa cells expressed activated ATM (57.5±17.8 vs. 
0.9± 0.7, p<0.001). A fraction of granulosa cells that co- 
Figure  5.  Doxorubicin  induces  double  strand  DNA 
breaks, activates ATM, and causes apoptosis in mouse 
oocytes. To study the in vivo effect of doxorubicin on mouse 
ovarian follicles and their cumulus cells, animals were injected 
with a single dose of doxorubicin 10 mg/kg. GV oocytes and 
small preantral follicles were retrieved 24h later from ovaries 
and  evaluated  by  confocal  microscopy.  A&B)  Doxorubicin 
treatment  leads  to  multinucleation  as  well  as  increased 
expression of  γH2AX. C&D) Doxorubicin-induces apoptosis of 
the  oocyte  and  surrounding  granulosa  cells  (arrows)  in 
association  with  the  induction  of  DSBs.  E&F)  Expression  and 
localization  of  ATM  in  oocytes  after  doxorubicin  treatment. 
While a higher amount of ATM is localized in the cytoplasm (cy) 
of the control oocytes (E), doxorubicin-treated oocytes show 
higher localization in the nucleus(nu)(F). G) Consistent with its 
impact on oocytes, ATM expression also increases in granulosa 
cells of small antral follicles after doxorubicin treatment (yellow 
arrows). H) Note that doxorubicin treatment induces DSBs in 
granulosa  cells  of  small  antral  follicles  (Split    channel  from 
image G). I) A minority of granulosa cells are non-apoptotic and 
express ATM indicating that DNA repair might have enabled 
them  to  overcome  genotoxic  stress  (yellow  arrows)  (split 
channel from image G). J) The majority experience apoptosis 
despite the activation of ATM (split channel from image G). 
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expressed ATM and γH2AX were not apoptotic (12.1± 
5.9%)  suggesting  that  ATM-mediated  repair  process 
was  still  ongoing  and  probably  preventing  cell  death 
(Figure 5, I). In majority however, apoptosis coincided 
with the co-expression of ATM and γH2AX (Figure 5, 
J),  indicating  that  the  DNA  repair  response  was  not 
sufficient to rescue granulosa cells from chemotherapy-
induced death. 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
 
Doxorubicin is a key chemotherapeutic agent used in 
the treatment of numerous malignancies such as breast, 
ovarian, and endometrial cancers as well as lymphomas, 
acute leukemias, and many others which are commonly 
encountered  during  the  premenopausal  ages 
[16,17,18,19]. In the present study we investigated the 
mechanism  of  chemotherapy-induced  ovarian  aging 
induced by this drug in vitro and in vivo on human and 
mice ovaries.  
 
We  found  that  doxorubicin,  in  a  dose-dependent 
fashion,  caused  massive  induction  of  γH2AX,  likely 
reporting  formation  of  DSBs  in  human  and  mouse 
oocytes,  as  confirmed  by  the  presence  of  multi-
nucleation  (Fig.  5  A&B)    and  comet  assay 
(Supplementary figure 1). The induction of DSBs was 
associated with apoptotic death of primordial follicles 
upon  exposure  to  doxorubicin.  Doxorubicin  activated 
ATM-mediated DSB repair pathways, which involved 
H2AX  phosphorylation  and  most  likely  activation  of 
other signaling pathways associated with DNA damage 
response [4]. It seems that following DNA damage not 
only  expression  of  activated  ATM  was  increased  but 
there was a significant translocation from the cytoplasm 
to the nucleus. Although ATM was originally thought to 
be a nuclear protein in proliferating cells, in oocytes it is 
predominantly cytoplasmic [20]. To our knowledge, this 
is the first observation of activated ATM behavior in 
oocytes. Further laboratory research will be needed to 
determine  the  function  of  cytoplasmic  ATM  and  the 
significance  of  the  translocation  process  to  ATM 
function in response to genotoxic stress. 
 
It is clear that the extent of doxorubicin-induced DNA 
damage  is  sufficient  to  induce  apoptotic  death  of  the 
majority  of  human  and  mouse  primordial  follicles. 
Apparently the repair mechanisms were inadequate to 
Figure 6. Comet assay with murine GV oocytes. Double strand DNA breaks were detected in murine GV 
oocytes using a single cell gel electrophoresis (Comet assay) after 24h culture with or without doxorubicin (10 
µg/ml).    Representative  images  of  non-treated  (A)  and  doxorubicin-treated  (B)  oocytes  are  shown.  (C) 
Quantification of DNA damage in control versus doxorubicin treated oocytes; expressed as mean (± SD) % of DNA 
in the tail. P = 0.002 (t-test). 
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Supplementary  Figure  1.  ATM  inhibitor  KU-55933  blocks 
activation of p63 in mouse oocytes response to genotoxic stress. 
Germinal vesicle stage oocytes from 6 week old FVB mice (n=14-
16/group) were treated without or with doxorubicin (1 μg/ml) 
for 24h in the presence or absence of KU-55933 (10 μMol) and 
were  subjected  to  confocal  microscopy.  Signal  intensity  for 
phospho-c-Abl (A) and phospho-TAp63 (B) were quantified using 
ImajeJ  software  (arbitrary  units,  AU).  (A)  KU-55933  inhibits 
doxo-induced  activation  of  c-Abl  (p<0.05)  but  not  the  basal 
levels  of  phospho-c-Abl;  (B)  KU-55933  completely  blocks 
activation of  p63 (p<0.05) both in  non  doxo-treated (p<0.05) 
and  doxo-treated  (p<0.05)  oocytes.  *  indicates  statistically 
significant difference from the doxo only group.  
rescue  them.  Our  findings,  however,  also  suggest  an 
intriguing possibility that the activation of ATM may 
result  in  the  rescue  of  a  considerable  minority  of 
oocytes  which  have  sustained  DSBs  due  to 
chemotherapy.  While  the  ATM-mediated  DSB  repair 
pathway is of high fidelity in nature and the majority of 
oocytes which were made to survive by this mechanism 
should have their DNA integrity restored, miss-repair or 
survival despite a failed repair is still possible[21]. This 
novel  concept  is  supported  by  our  demonstration  of 
reduction  of  chemotherapy-induced  apoptotic  death 
after the treatment of oocytes with ATM inhibitor KU-
55933.    While  in  somatic  cells,  inhibition  of  DNA 
repair  mechanisms  may  be  expected  to  increase 
sensitivity to chemotherapeutics in general [22], germ 
cells  seem  to  have  a  different  behavior.  In  oocytes, 
TAp63α,  a  pro-apoptotic  P53  family  member  with 
specificity to germ line, is activated in response to DNA 
damage and causes apoptotic death [13,15]. TAp63α is 
activated  by  c-Abl,  which  is  a  non-receptor  tyrosine 
kinase involved in many cellular processes, in response 
to  DNA  damage.  It  has  been  shown  that  ATM  is 
involved in activation of c-Abl after DNA damage [14]. 
Our  finding  that  ATM  inhibition  reduces  apoptotic 
oocyte  death  after  DNA  damage,  while  blocking 
TAp63α and c-Abl activation, is consistent with ATM’s 
role  in  activation  of  the  c-Abl-TAp63  pathway.  We 
found  that  ATM  inhibition  had  a  more  profound 
negative effect on  Tap63α activation than c-Abl (Suppl. 
Fig. 1), suggesting that ATM might also be regulating  
doxo-induced TAp63α  activation independent of c-Abl 
in  oocytes.  Our  findings  are  also  in  parallel  with  the 
data showing that ATM has a pro-apoptotic function in 
DNA-damaged neurons of  developing  mouse CNS,  in 
collaboration with the Bax protein [23,24,25,26,27].  It 
was  observed  in  these  previous  studies  that  ATM−/− 
mice  exhibited  resistance  to  ionizing  radiation-
induced apoptosis in  diverse  regions  of  the 
developing CNS. In wild-type but not ATM−/− mice, 
up-regulation  of  p53  coincided  with cell  death, 
suggesting  that  ATM-dependent apoptosis in 
the CNS was  mediated  by  p53.  Furthermore,  p53-null 
animals exhibited similar lack of radiation-induced cell 
death in  the  developing nervous  system.  These  results 
are in correlation with our findings in the ovary, and 
suggest  that  ATM  may  function  at  a  developmental 
survival checkpoint that serves to eliminate cells with 
excessive DNA damage[23,25,26] [27,28] . 
 
This brings the next question of whether unrepaired or 
mis-repaired DSBs can culminate into severe mutagenic 
changes  in  the  surviving  primordial  follicles.  Even 
though clinical data do not suggest an increase in the 
incidence of genetic disorders in children born to cancer 
survivors, the power of such studies is limited [29,30]. 
Of  concern,  a  recent  rodent  study  showed  increased 
rates  of  neonatal  death,  physical  malformations,  and 
chromosomal  abnormalities  in  up  to  6  generations  of 
offspring after exposure to single dose of doxorubicin 
[31].  Because  unrepaired  DSBs  can  result  in  severe 
mutagenesis  and  can  explain  these  new  findings  in 
laboratory  animals,  it  will  be  of  great  importance  to 
study the accumulation of DSBs in long term human 
ovarian xenografting experiments as well as in vivo in 
mice.    However,  we  found  from  our  in  vitro 
experiments with mouse oocytes that even though ATM 
inhibition rescued oocytes from chemotherapy-induced 
death, it did not prevent the arrest of their growth at M-I 
stage.  This  indicates  that  there  are  cell  cycle  check 
mechanisms  independent  of  ATM  which  can  sense 
lethal DNA damage and prevent propagation of severe 
mutations. It is possible that in humans too, even though 
some  primordial  follicles  may  survive  chemotherapy 
exposure despite the presence of significant DSBs, their 
growth  may  be  halted  after  ovulation  triggers  the 
resumption of cell cycle from prophase-I. Because cell 
cycle  check  mechanisms  would  prevent  such  oocytes 
from  becoming  mature  and  advancing  to  M-II  stage, 
they  cannot  be  fertilized  to  become  embryos.  This 
hypothesis  is  consistent  with  our  previous  clinical 
findings  that  women  with  seemingly  normal  ovarian 
reserve  post-chemotherapy  have  significantly  lower 
pregnancy rates with in vitro fertilization compared to 
age-matched  controls  [32].    Hence  women  whose 
ovarian function has survived chemotherapy may still 
be at risk for infertility due to this occult DNA damage 
in their remaining oocytes. 
 
Why  some  ovarian  follicles  die  after  chemotherapy 
while  others  survive  in  the  same  environment?  It  is 
possible that some oocytes may survive chemotherapy 
without DNA damage due to their individual resistance 
to  chemotherapy  through  yet  undefined  mechanisms.  
One such possible mechanism is the difference in the 
efficiency of DNA repair in individual oocytes. Data are 
already accumulating that effective DSB repair is vital 
for oocyte survival [33]. It is possible that those oocytes 
which inherently are more efficient in DNA repair are 
more  likely  to  be  resistant  to  chemotherapy-induced 
DSBs and cell death. The opposite is also possible that 
the  absence  of  ATM  response  is  responsible  for  the 
perceived  survival  of  ovarian  follicles  after 
chemotherapy.  From  our  experiments  showing  that 
ATM inhibition reduces apoptotic oocyte death, it can 
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be  speculated  that  some  oocytes  that  survive  despite 
chemotherapy  exposure  might  have  deficient  ATM 
response,  which  fails  to  initiate  TAp63α  dependent 
death,  allowing  survival  despite  the  persistence  of 
DSBs. If such individual differences exist, exploration 
of factors regulating DSB repair in oocytes may result 
in  the  development  of  new  therapeutic  strategies  to 
protect  oocytes  by  enhancing  DNA  repair  efficiency 
and preserve fertility in the face of chemotherapy. 
 
It should be noted the survival of primordial follicles 
was presently observed at relatively short time (24–72 
h)  of  exposure  to  chemotherapy  in  organ  cultures  or 
xenografts (figs 2 and 3). It is possible that some of the 
“surviving” oocytes were actually undergoing cellular 
senescence,  the  state  of  reproductive  cell  death  with 
preservation of physical and metabolic integrity [34]. In 
fact,  the  mechanism  of  chemotherapy-induced  growth 
inhibition of tumors often involves  both, induction of 
apoptosis  and  irreversible  impairment  of  cell 
reproductive  capacity,  defined  as  “senescence-like 
growth  arrest”,    “premature  senescence”    or  “drug-
induced  senescence”  [34,35,36].  Further  research  will 
be  needed  to  determine  whether  meiotic  cells  i.e. 
oocytes can also experience this form of senescence. 
 
Another novel finding from our studies is the ability of 
doxorubicin  to  damage  human  ovarian 
microvasculature. We found that doxorubicin causes a 
decline  in  microvascular  density  in  a  dose-dependent 
fashion.  While  we  cannot  prove  that  microvascular 
damage  directly  contributes  to  chemotherapy-induced 
follicle  death,  in  prior  studies  we  showed  an  inverse 
correlation  between  human  ovarian  microvascular 
density  and  primordial  follicle  apoptosis[5].  It  is 
generally believed that the human primordial follicles 
are not acutely dependent on perfusion but the clinical 
experience from ovarian transplantation[37]  as well as 
acute ovarian ischemia (ovarian torsion) cases do not 
support this general belief[38] . While larger follicles 
may be more sensitive to acute ischemic changes due to 
a  greater  mass  of  proliferating  granulosa  cells,  our 
experimental models clearly support the dependence of 
primordial  follicles  on  adequate  vascularization  [5]. 
Given this background, it is possible that chemotherapy-
induced  ovarian  vascular  damage  is  a  contributing 
factor to the loss of primordial follicle reserve and aging 
in human ovary.   
 
Furthermore,  ovarian  tissue  is  a  functional  endocrine 
organ  even  after  natural  menopause  or  premature 
ovarian  failure,  and  continues  to  produce  critical  sex 
steroids such as testosterone and estrogen. We not only 
showed that doxorubicin-induces microvascular damage 
but it also damages ovarian stroma. Hence it is likely 
that  even  as  a  postmenopausal  senescent  organ,  the 
human  ovary  becomes  dysfunctional  after 
chemotherapy.  In  keeping  with  this  concept,  we 
previously showed that chemotherapy exposed ovarian 
stromal  tissue  produces  lower  levels  of  estradiol 
compared to controls [39]. 
 
Our findings have strong clinical implications. A large 
number of young females receive doxorubicin as part of 
their treatment for cancer. Doxorubicin treatment may 
not only be compromising the future fertility potential 
and  accelerating  ovarian  aging  in  these  young  cancer 
survivors but can also be placing them at disadvantage 
during their postmenopausal years. Women undergoing 
chemotherapy  with  doxorubicin  containing  regimens 
must  undergo  adequate  counseling  to  weigh  their 
options  for  established  and  experimental  fertility 
preservation options [40](9). While oocyte and embryo 
cryopreservation  can  be  utilized  to  preserve  future 
fertility,  ovarian  cryopreservation  for  future 
transplantation  is  the  only  modality  that  can  restore 
natural ovarian function and circumvent chemotherapy-
induced  premature  ovarian  senescence  [41,42].  Given 
our  findings  that  the  chemotherapy-exposed  human 
ovary  may  not  function  as  a  normal  postmenopausal 
organ and show accelerated senescence, ovarian tissue 
freezing may be selectively attractive to some survivors. 
More  importantly,  given  these  complex  damaging 
effects of cancer drugs on human ovarian function, less 
toxic drugs should be developed, or elected when they 
are available. And finally, understanding the mechanism 
of accelerated senescence by cancer drugs may enable 
us  to  develop  targeted  pharmacological  ovarian 
preservation methods. 
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